Download PDF
Horm Metab Res 2013; 45(02): 169-172
DOI: 10.1055/s-0032-1323844
Humans, Clinical
© Georg Thieme Verlag KG Stuttgart · New York

Circulating Very-Low-Density Lipoprotein from Subjects with Impaired Glucose Tolerance Accelerates Adrenocortical Cortisol and Aldosterone Synthesis

S. Saha
1   Department of Internal Medicine 3, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
,
P.E. H. Schwarz
1   Department of Internal Medicine 3, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
,
S. Bergmann
2   Institute of Clinical Chemistry and Laboratory Medicine, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
,
S. R. Bornstein
1   Department of Internal Medicine 3, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
,
J. Graessler
1   Department of Internal Medicine 3, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
,
S. Kopprasch
1   Department of Internal Medicine 3, Carl Gustav Carus Medical School, Technical University of Dresden, Dresden, Germany
› Author Affiliations
Further Information

Publication History

received 14 June 2012

accepted 29 August 2012

Publication Date:
09 October 2012 (online)

Also available at
    Permissions and Reprints

Abstract

Apart from their role in cardiovascular homeostasis and immunomodulation, aldosterone and cortisol are also implicated in the pathogenesis of insulin resistance and type 2 diabetes mellitus (T2DM). Furthermore, glycoxidative modifications of lipoproteins are increasingly recognized as an etiological factor for increased cardiovascular morbidity and mortality in prediabetic individuals. The causative relationship between in vivo lipoprotein modifications and steroidogenesis in subjects with impaired glucose tolerance (IGT), however, is not well defined. Therefore, we aimed to investigate the impact of in vivo modified lipoproteins on aldosterone and cortisol release from human adrenocortical H295R cells. Following an oral glucose tolerance test, 20 individuals with normal glucose tolerance (NGT) and 20 IGT subjects were randomly selected from the ongoing PRAEDIAS prevention study in our department. Cells were incubated for 24 h with lipoproteins isolated from NGT and IGT individuals and aldosterone and cortisol release was measured in the supernatants. VLDL induced a greater stimulating effect on adrenocortical aldosterone and cortisol release compared to HDL and LDL. Moreover, IGT-VLDL evoked a significantly higher effect (p<0.05) on hormone release than NGT-VLDL. Incubation of cells with in vitro modified lipoproteins and specific pharmacological inhibitors suggests that VLDL presumably recruits ERK1/2 as one of the downstream effectors of Jak-2. In summary, in vivo modified VLDL are able to promote prediabetic hormonal dysregulation by modulating adrenocortical steroidogenesis via Jak-2-ERK dependent pathway.

Key words

adrenal gland - lipoproteins - aldosterone - cortisol
 

  • References

  • 1 Liang F, Kapoun AM, Lam A, Damm DL, Quan D, O’Connell M, Protter AA. B-Type natriuretic peptide inhibited angiotensin II-stimulated cholesterol biosynthesis, cholesterol transfer, and steroidogenesis in primary human adrenocortical cells. Endocrinology 2007; 148: 3722-3729
    CrossrefPubMedGoogle Scholar
  • 2 Saha S, Bornstein SR, Graessler J, Kopprasch S. Very-low-density lipoprotein mediates transcriptional regulation of aldosterone synthase in human adrenocortical cells through multiple signaling pathways. Cell Tissue Res 2012; 348: 71-80
    CrossrefPubMedGoogle Scholar
  • 3 Xing Y, Rainey WE, Apolzan JW, Francone OL, Harris RB, Bollag WB. Adrenal Cell Aldosterone Production Is Stimulated by Very-Low-Density Lipoprotein (VLDL). Endocrinology 2012; 153: 721-731
    CrossrefPubMedGoogle Scholar
  • 4 Saha S, Willenberg HS, Bornstein SR, Graessler J, Kopprasch S. Diabetic lipoproteins and adrenal aldosterone synthesis–a possible pathophysiological link?. Horm Metab Res 2012; 44: 239-244
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Braschi S, Geoffrion M, Nguyen A, Gaudreau Y, Milne RW. The expression of apolipoprotein B epitopes is normal in LDL of diabetic and end-stage renal disease patients. Diabetologia 2006; 49: 1394-1401
    CrossrefPubMedGoogle Scholar
  • 6 Adiels M, Olofsson SO, Taskinen MR, Boren J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 1225-1236
    CrossrefPubMedGoogle Scholar
  • 7 Goodfriend TL, Egan B, Stepniakowski K, Ball DL. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension 1995; 25: 30-36
    CrossrefPubMedGoogle Scholar
  • 8 Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus high sodium diet on blood pressure, renin, aldosterone, catecholamines, cholesterol, and triglyceride. Cochrane Database Syst Rev 2011; (11) CD004022
    PubMedGoogle Scholar
  • 9 Lopes HF, Silva HB, Soares JA, Filho B, Consolim-Colombo FM, Giorgi DM, Krieger EM. Lipid metabolism alterations in normotensive subjects with positive family history of hypertension. Hypertension 1997; 30: 629-631
    CrossrefPubMedGoogle Scholar
  • 10 Quinkler M, Born-Frontsberg E, Fourkiotis VG. Comorbidities in primary aldosteronism. Horm Metab Res 2010; 42: 429-434
    Google Scholar
  • 11 Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, Bidlingmaier M, Seissler J, Endres S. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn’s Registry. Horm Metab Res 2010; 42: 435-439
    Google Scholar
  • 12 Andrews RC, Herlihy O, Livingstone DE, Andrew R, Walker BR. Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance. J Clin Endocrinol Metab 2002; 87: 5587-5593
    CrossrefPubMedGoogle Scholar
  • 13 Graessler J, Pietzsch J, Westendorf T, Julius U, Bornstein SR, Kopprasch S. Glycoxidised LDL isolated from subjects with impaired glucose tolerance increases CD36 and peroxisome proliferator-activator receptor gamma gene expression in macrophages. Diabetologia 2007; 50: 1080-1088
    CrossrefPubMedGoogle Scholar
  • 14 Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J. Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 1711-1716
    CrossrefPubMedGoogle Scholar
  • 15 Pietzsch J, Subat S, Nitzsche S, Leonhardt W, Schentke KU, Hanefeld M. Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim Biophys Acta 1995; 1254: 77-88
    CrossrefPubMedGoogle Scholar
  • 16 Younis N, Charlton-Menys V, Sharma R, Soran H, Durrington PN. Glycation of LDL in non-diabetic people: Small dense LDL is preferentially glycated both in vivo and in vitro. Atherosclerosis 2009; 202: 162-168
    CrossrefPubMedGoogle Scholar
  • 17 Younis N, Sharma R, Soran H, Charlton-Menys V, Elseweidy M, Durrington PN. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol 2008; 19: 378-384
    CrossrefPubMedGoogle Scholar
  • 18 Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 1990; 186: 464-478
    PubMedGoogle Scholar
  • 19 Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234
    CrossrefPubMedGoogle Scholar
  • 20 Bruehl H, Rueger M, Dziobek I, Sweat V, Tirsi A, Javier E, Arentoft A, Wolf OT, Convit A. Hypothalamic-pituitary-adrenal axis dysregulation and memory impairments in type 2 diabetes. J Clin Endocrinol Metab 2007; 92: 2439-2445
    CrossrefPubMedGoogle Scholar
  • 21 Kantorovich V, Koch CA, Chrousos GP. Hypertension in patients with Cushing syndrome. In: Koch CA, Chrousos GP. (eds.). Endocrine Hypertension. New York: Springer; 2012
    Google Scholar
  • 22 Melcescu E, Griswold M, Xiang L, Belk S, Montgomery D, Bray M, Delben KS, Uwaifo GI, Marshall GD, Koch CA. Prevalence and cardiometabolic associations of the glucocorticoid receptor gene polymorphisms N363S and BclI in obese and non-obese black and white Mississippians. Hormones (Athens) 2012; 11: 166-177
    PubMedGoogle Scholar
  • 23 Bassett MH, White PC, Rainey WE. The regulation of aldosterone synthase expression. Mol Cell Endocrinol 2004; 217: 67-74
    CrossrefPubMedGoogle Scholar
  • 24 Pilon A, Martin G, Bultel-Brienne S, Junquero D, Delhon A, Fruchart JC, Staels B, Clavey V. Regulation of the scavenger receptor BI and the LDL receptor by activators of aldosterone production, angiotensin II and PMA, in the human NCI-H295R adrenocortical cell line. Biochim Biophys Acta 2003; 1631: 218-228
    CrossrefPubMedGoogle Scholar
  • 25 Li J, Feltzer RE, Dawson KL, Hudson EA, Clark BJ. Janus kinase 2 and calcium are required for angiotensin II-dependent activation of steroidogenic acute regulatory protein transcription in H295R human adrenocortical cells. J Biol Chem 2003; 278: 52355-52362
    CrossrefPubMedGoogle Scholar
  • 26 Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153
    CrossrefPubMedGoogle Scholar